Ottawa, ON /
ACCESSWIRE / Jul 18 2014 / - Avivagen
Inc. (TSXV: VIV), a wellness company developing and delivering
products that support and enhance the health and quality of life
for animals and the people who care for them, today announced an
agreement with Nam Sai Farms Co. Ltd. of the Kingdom of Thailand to
conduct a trial to determine the effects of OxC-beta on the
grow-out parameters of tilapia.
Tilapia are commercially-important
aquaculture species, typically grown in fresh water ponds in warm
climates. Approximately four million tons of tilapia are raised
annually, mainly from China, Egypt, Indonesia, Philippines,
Thailand and Brazil. As a warm climate and fresh water fish,
Tilapia can be affected by bacterial pathogens in the production
ponds, with streptococcus infection being one of the most
significant producer challenges. As with many bacterial pathogens
that occur in food animals, streptococci are also a source of human
disease.
The trial is entitled "Commercial investigation into the
effects of OxC-beta dietary addition on performance of red tilapia
grown out in cages." It will test the effects of two different
levels of OxC-beta and a positive control product against a
negative control on the grow-out parameters of tilapia raised in
cages in an earthen reservoir. Five replicates of each treatment
group will be conducted, for a total of 20 groups of 300 fish each.
The grow-out period is expected to take approximately six months to
complete, following which a final study report will be
prepared.
This trial is intended to determine
the efficacy of OxC-beta under commercial tilapia production
conditions, measuring parameters of economic interest to producers.
Parameters monitored will include growth, weight and feed
conversion measurements, among other considerations.
The trial design was a collaborative
effort between Nam Sai Farms, Avivagen's Asia-based consultants,
its Thai distributor Natural Nutrients Co., Ltd. and Dr. Jamie
Nickerson, Avivagen's Director of Product Validation and head of
its Charlottetown-based biology research unit. The trial will be
conducted in Prachunburi province of Thailand and is expected to be
concluded during the first half of calendar 2015.
Cameron Groome, CEO and President,
commented on this trial, "Avivagen-sponsored studies are important
as they provide specific guidance to producers about how best to
use OxC-beta. Such trials may also provide publishable results in
support of national product registrations and species-specific
marketing claims. This third new Avivagen-sponsored trial is in
addition to trials designed and run by prospective commercial
customers, some of which are ongoing and others that are in the
planning stages. However, unlike Avivagen-sponsored trials, results
of customer-sponsored OxC-beta trials may not be reported other
than by way of resulting product sales."
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of
the National Research Council of Canada (NRC) - in Ottawa, Ontario
and Charlottetown, Prince Edward Island. More information can be
found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research results indicate OxC-beta supports innate immune
function, which can help maintain good health. In pets, OxC-beta
supports overall vitality and energy, mobility and joint function,
skin, coat and gut. Results observed in food animals have included
healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for livestock,
Vivamune(TM) Health Chews and Oximunol(TM) Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold
in 1.0 or 5.0 Kg quantities for parts-per-million addition to
animal feeds, in accordance with producer-developed protocols. In
past studies, OxC-beta has been shown to support health or growth
in species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews - For
dogs and cats
Vivamune(TM) Health Chews, containing Avivagen's
proprietary active ingredients, are scientifically-formulated chews
for dogs and cats. Vivamune(TM) Health Chews work with a pet's own
immune system to maintain overall health and well-being. They are
sold in re-sealable packages of 30 chews and are currently
available in the United States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM) Chewables - For
dogs
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
Permanent Non-Surgical Sterilization
of Female Mammals
Avivagen has optioned worldwide exclusive rights to a technology
for the permanent and non-surgical sterilization of female mammals.
A proof-of-concept trial in an indicative species will soon be
started in order to demonstrate whether the technology appears to
be safe and effective. It is expected that a patent application
covering World Trade Organization countries will be pursued and
that technological details will be made available when that patent
application is published. Further information will be disclosed as
deemed prudent or as required.
Forward
Looking Statements
This news release includes certain
forward-looking statements that are based upon current
expectations, which involve risks and uncertainties associated with
the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions "anticipated",
"believe", "could", "estimated", "expected", "if", "intended",
"likely", "may", "plan", "possibly", "potentially", "should",
"whether", "will", "would" and similar expressions. Statements
about Avivagen's beliefs about the viability and potential future
applications of the technologies described in this news release,
including the results of the proposed tilapia study, the timing of
the study, the timing of the receipt of the study results, whether
the trial results in any publishable material or can support
product registrations or species-specific claims, their commercial
relevance, novelty and proposed uses, whether or not they are
patentable, and whether or not they infringe the intellectual
property rights of third parties and statements about their
potential markets are all forward looking statements. The
forward-looking statements reflect the current expectations of
Avivagen Inc. regarding future results or events relating to its
business generally and the specific subject matters of this news
release. These forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results or
events to differ materially from current expectations. Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
www.avivagen.com
SOURCE: Avivagen Inc.
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
